甲氨蝶呤中毒的体外治疗:EXTRIP工作组的系统评价与推荐
甲氨蝶呤用于多种恶性肿瘤、风湿病和炎症性肠病,中毒可致严重并发症和死亡,解救包括静脉水化、亚叶酸和部分中心的葡萄糖苷酶。EXTRIP工作组按系统评价方法检索文献,共92篇符合纳入标准,按GRADE分级并采用改良Delphi法投票形成推荐。毒代动力学数据来自90例患者(89例肾功能受损),甲氨蝶呤经间歇性血液透析被认为中等可透析;临床分析109例(高剂量>0.5 g/m2 91例,低剂量≤0.5 g/m2 18例),高剂量和低剂量相关毒性总体死亡率分别为19.5%和26.7%。工作组对严重中毒接受标准治疗者给出3条推荐:未用葡萄糖苷酶时建议不(弱推荐)体外治疗;使用葡萄糖苷酶时推荐不(强推荐)体外治疗;推荐不(强推荐)以体外治疗替代葡萄糖苷酶;证据质量极低。
要点
- 严重甲氨蝶呤中毒接受标准治疗且未用葡萄糖苷酶者,EXTRIP建议不(弱推荐)采用体外治疗,证据质量极低。
- 严重甲氨蝶呤中毒已使用葡萄糖苷酶者,EXTRIP推荐不(强推荐)采用体外治疗,证据质量极低。
- EXTRIP推荐不(强推荐)以体外治疗替代葡萄糖苷酶,证据质量极低。
- 甲氨蝶呤经间歇性血液透析被认为中等可透析;毒代动力学数据来自90例患者,其中89例肾功能受损。
- 高剂量(>0.5 g/m2)和低剂量(≤0.5 g/m2)甲氨蝶呤相关毒性死亡率分别为19.5%和26.7%,但一项观察性研究存在重要局限。
适用人群与场景
- 严重甲氨蝶呤毒性且接受标准治疗的患者。
- 临床分析109例中,高剂量甲氨蝶呤(>0.5 g/m2)91例,低剂量(≤0.5 g/m2)18例。
处置流程与药物剂量
- 标准解救治疗包括静脉水化、亚叶酸,部分中心使用葡萄糖苷酶。
研究设计与关键结果
- 系统评价共纳入92篇文章;毒代动力学数据来自90例患者,其中89例肾功能受损。
- 甲氨蝶呤经间歇性血液透析被认为中等可透析。
- 临床分析纳入109例患者(高剂量>0.5 g/m2 91例,低剂量≤0.5 g/m2 18例),高剂量和低剂量相关毒性总体死亡率分别为19.5%和26.7%。
- 一项观察性研究报道葡萄糖苷酶治疗者死亡率低于血液透析治疗者,但该研究存在重要局限。
证据类型、等级与局限
- 证据类型:系统评价与推荐(EXTRIP工作组),采用GRADE分级和改良Delphi法投票。
- 推荐质量:极低。
- 局限:一项观察性研究存在重要局限;推荐证据质量极低。
对床旁实践的改变
- EXTRIP工作组建议不(弱推荐)对未使用葡萄糖苷酶的严重甲氨蝶呤中毒接受标准治疗者采用体外治疗。
- EXTRIP工作组推荐不(强推荐)对已使用葡萄糖苷酶的严重甲氨蝶呤中毒者采用体外治疗。
- EXTRIP工作组推荐不(强推荐)以体外治疗替代葡萄糖苷酶。
- 理由包括:体外治疗主要清除血管内药物而甲氨蝶呤快速分布至细胞;体外治疗清除亚叶酸;需快速清除甲氨蝶呤的罕见情况下葡萄糖苷酶优于任何体外治疗;体外治疗似乎不降低甲氨蝶呤毒性的发生率和程度。
指南或共识出处
- EXTRIP工作组系统评价与推荐,发表于Clin J Am Soc Nephrol。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Methotrexate is used in the treatment of many malignancies, rheumatological diseases, and inflammatory bowel disease. Toxicity from use is associated with severe morbidity and mortality. Rescue treatments include intravenous hydration, folinic acid, and, in some centers, glucarpidase. We conducted systematic reviews of the literature following published EXtracorporeal TReatments In Poisoning (EXTRIP) methods to determine the utility of extracorporeal treatments in the management of methotrexate toxicity. The quality of the evidence and the strength of recommendations (either "strong" or "weak/conditional") were graded according to the GRADE approach. A formal voting process using a modified Delphi method assessed the level of agreement between panelists on the final recommendations. A total of 92 articles met inclusion criteria. Toxicokinetic data were available on 90 patients (89 with impaired kidney function). Methotrexate was considered to be moderately dialyzable by intermittent hemodialysis. Data were available for clinical analysis on 109 patients (high-dose methotrexate [>0.5 g/m2]: 91 patients; low-dose [≤0.5 g/m2]: 18). Overall mortality in these publications was 19.5% and 26.7% in those with high-dose and low-dose methotrexate-related toxicity, respectively. Although one observational study reported lower mortality in patients treated with glucarpidase compared with those treated with hemodialysis, there were important limitations in the study. For patients with severe methotrexate toxicity receiving standard care, the EXTRIP workgroup: (1) suggested against extracorporeal treatments when glucarpidase is not administered; (2) recommended against extracorporeal treatments when glucarpidase is administered; and (3) recommended against extracorporeal treatments instead of administering glucarpidase. The quality of evidence for these recommendations was very low. Rationales for these recommendations included: (1) extracorporeal treatments mainly remove drugs in the intravascular compartment, whereas methotrexate rapidly distributes into cells; (2) extracorporeal treatments remove folinic acid; (3) in rare cases where fast removal of methotrexate is required, glucarpidase will outperform any extracorporeal treatment; and (4) extracorporeal treatments do not appear to reduce the incidence and magnitude of methotrexate toxicity.
参考来源
- Ghannoum M, Roberts DM, Goldfarb DS, et al. Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Clin J Am Soc Nephrol. 2022. PMID: 35236714. doi:10.2215/CJN.08030621
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。